A Comparison Between 12 Versus 20 Weeks of Trimethoprim-Sulfamethoxazole as Oral Eradication Treatment for Melioidosis (12vs20): An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
Clicks: 308
ID: 111200
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
308 views
57 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #15 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
AbstractBackground. Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (17 words).
Try re-searching for a better abstract.
| Reference Key |
siriluckclinicala
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Anunnatsiri, Siriluck;Chaowagul, Wipada;Teparrukkul, Prapit;Chetchotisakd, Ploenchan;Tanwisaid, Kittisak;Khemla, Supphachoke;Narenpitak, Surapong;Pattarapongsin, Moragot;Kongsawasd, Wirod;Pisuttimarn, Pornrith;Thipmontree, Wilawan;Mootsikapun, Piroon;Chaisuksant, Seksan;Chierakul, Wirongrong;Day, Nicholas P J;Limmathurotsakul, Direk; |
| Journal | clinical infectious diseases |
| Year | Year not found |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.